Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 5:21 pm Purchase | 2026-06-30 | 13G | X4 PHARMACEUTICALS INC XFOR | Perceptive Advisors LLC | 8,085,006 8.100% | 1,195,843 (+17.36%) | Filing History |
| 2026-08-14 08:34 am Purchase | 2026-06-30 | 13G | X4 PHARMACEUTICALS INC XFOR | Deep Track Capital, LP | 8,040,894 8.330% | 5,673,899 (+239.71%) | Filing History |
| 2026-07-30 11:18 am Purchase | 2026-06-30 | 13G | X4 PHARMACEUTICALS INC XFOR | BlackRock, Inc. BLK | 5,529,573 5.900% | 5,350,448 (+2986.99%) | Filing History |
| 2026-05-15 4:00 pm Purchase | 2026-03-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Perceptive Advisors LLC | 6,889,163 7.300% | 824,483 (+13.59%) | Filing History |
| 2026-03-06 4:24 pm Purchase | 2026-02-28 | 13G | X4 PHARMACEUTICALS INC XFOR | Morgan Stanley MS | 8,884,338 10.200% | 687,849 (+8.39%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | BIOTECHNOLOGY VALUE FUND L P | 3,411,993 3.900% | 1,168,334 (+52.07%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Trails Edge Capital Partners, LP | 5,227,222 5.800% | 2,910,069 (+125.59%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Bain Capital Life Sciences Fund, L.P. | 7,047,216 7.430% | 4,610,628 (+189.22%) | Filing History |
| 2026-02-17 2:46 pm Purchase | 2025-10-24 | 13G | X4 PHARMACEUTICALS INC XFOR | Saturn V Capital Management LP | 6,433,481 7.360% | 6,433,481 (New Position) | Filing History |
| 2026-02-13 5:09 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Nantahala Capital Management LLC | 2,449,468 2.800% | 205,149 (+9.14%) | Filing History |
| 2026-02-12 2:28 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Morgan Stanley MS | 8,196,489 9.400% | 8,196,489 (New Position) | Filing History |
| 2026-02-05 2:07 pm Unchanged | 2025-10-31 | 13G | X4 PHARMACEUTICALS INC XFOR | FMR LLC | 8,499,100 9.700% | 0 (Unchanged) | Filing History |
| 2026-01-15 1:21 pm Purchase | 2025-12-31 | 13G | X4 PHARMACEUTICALS INC XFOR | Empery Asset Management, LP | 9,043,894 9.990% | 6,545,732 (+262.02%) | Filing History |
| 2025-11-14 4:39 pm Purchase | 2025-09-30 | 13G | X4 PHARMACEUTICALS INC XFOR | Nantahala Capital Management LLC | 2,244,319 9.990% | 2,244,319 (New Position) | Filing History |
| 2025-11-07 11:13 am Purchase | 2025-10-31 | 13G | X4 PHARMACEUTICALS INC XFOR | FMR LLC | 8,499,100 14.800% | 8,471,857 (+31097.37%) | Filing History |
| 2025-11-03 4:09 pm Purchase | 2025-10-27 | 13G | X4 PHARMACEUTICALS INC XFOR | Perceptive Advisors LLC | 6,064,680 7.600% | 6,064,680 (New Position) | Filing History |
| 2025-10-29 6:04 pm Purchase | 2025-10-27 | 13D | X4 PHARMACEUTICALS INC XFOR | Growth Equity Opportunities 18 VGE, LLC | 5,057,610 6.200% | 2,813,952 (+125.42%) | Filing History |
| 2025-10-21 09:00 am Purchase | 2025-09-30 | 13G | X4 PHARMACEUTICALS INC XFOR | Empery Asset Management, LP | 2,498,162 9.990% | 2,346,508 (+1547.28%) | Filing History |
| 2025-10-03 5:25 pm Purchase | 2025-10-03 | 13G | X4 PHARMACEUTICALS INC XFOR | Coastlands Capital LP | 2,491,638 9.990% | 11,993 (+0.48%) | Filing History |
| 2025-09-15 4:30 pm Purchase | 2025-09-09 | 13G | X4 PHARMACEUTICALS INC XFOR | Bain Capital Life Sciences Fund, L.P. | 2,436,588 9.990% | 62 (+0.00%) | Filing History |